New stock news | Meigene Biotechnology plans to list in Hong Kong IPO. The China Securities Regulatory Commission requires additional information on the progress of handling the identification of state-owned shareholders in Zhangjiang Ke Investment.

According to the Zhitong Financial APP, on September 26, the China Securities Regulatory Commission issued the "Supplementary Materials Requirements for Overseas Issuance and Listing Filing (September 19, 2025 to September 25, 2025)", and the International Department of the China Securities Regulatory Commission issued supplementary material requirements for 5 companies. In the announcement, the CSRC requested Maizi Biology to provide supplementary explanations on the progress of identifying the state-owned shareholder of Zhangjiang Ke Investment, as well as the pricing basis for Maizi Limited's historical capital increases and equity transfers. According to the disclosure of the Hong Kong Stock Exchange on July 14, Hunan Maizi Biotechnology Co., Ltd. (referred to as Maizi Biology) submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with China International Capital Corporation as the exclusive sponsor.